Quotes 5-day view Delayed Nasdaq
05/12/2022
05/13/2022
05/16/2022
05/17/2022
05/18/2022
Date
194.32(c)
199.11(c)
198.38(c)
202.9(c)
195.78
Last
1 313 884
1 230 538
831 474
781 913
716 882
Volume
+1.70%
+2.47%
-0.37%
+2.28%
-3.51%
Change
Estimated financial data (e) (USD)
Sales 2022
9 837 M
-
-
Net income 2022
2 005 M
-
-
Net cash position 2022
60,0 M
-
-
P/E ratio 2022
14,4x
Yield 2022
-
Sales 2023
9 405 M
-
-
Net income 2023
2 284 M
-
-
Net cash position 2023
3 250 M
-
-
P/E ratio 2023
12,5x
Yield 2023
-
Capitalization
29 715 M
29 715 M
-
EV / Sales 2022
3,01x
EV / Sales 2023
2,81x
Nbr of Employees
9 610
Free-Float
85,4%
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (80.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (15.1%) ;
- other (4.4%): primarily revenues from partnership agreements.
All news about BIOGEN INC.
News in other languages on BIOGEN INC.
Analyst Recommendations on BIOGEN INC.
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIOGEN INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
202,90 $
Average target price
245,90 $
Spread / Average Target
21,2%
Please enable JavaScript in your browser's settings to use dynamic charts.